Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Bioventus (BVS) over the last 5 years, with Q3 2025 value amounting to $2.8 million.

  • Bioventus' Treasury Shares rose 132.14% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 132.14%. This contributed to the annual value of $2.4 million for FY2024, which is 1674.73% up from last year.
  • According to the latest figures from Q3 2025, Bioventus' Treasury Shares is $2.8 million, which was up 132.14% from $2.9 million recorded in Q2 2025.
  • Bioventus' 5-year Treasury Shares high stood at $3.9 million for Q1 2024, and its period low was $183078.0 during Q3 2021.
  • For the 5-year period, Bioventus' Treasury Shares averaged around $1.9 million, with its median value being $2.1 million (2023).
  • As far as peak fluctuations go, Bioventus' Treasury Shares soared by 59369.34% in 2022, and later tumbled by 2515.87% in 2025.
  • Bioventus' Treasury Shares (Quarter) stood at $1.0 million in 2021, then grew by 16.11% to $1.2 million in 2022, then soared by 73.76% to $2.1 million in 2023, then grew by 16.75% to $2.4 million in 2024, then rose by 17.62% to $2.8 million in 2025.
  • Its Treasury Shares was $2.8 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.9 million in Q1 2025.